This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Bright Peak Therapeutics Ag. Active years: 2023-2026.
Company Filing History:
Years Active: 2023-2026
Title: Innovations of Régis Boehringer in Modified IL-2 Polypeptides
Introduction
Régis Boehringer is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of biomedicine, particularly in the development of modified IL-2 polypeptides. His work focuses on innovative treatments for diseases, including cancer.
Latest Patents
Régis Boehringer holds a patent for "Modified IL-2 polypeptides and uses thereof." This patent encompasses modified IL-2 polypeptides, compositions that include these polypeptides, and methods for their production and application. The invention highlights the potential of these modified IL-2 polypeptides in treating cancer by exhibiting preferential binding characteristics to the IL-2 receptor βγ complex over the IL-2 receptor αβγ complex. The molecular weight distribution of these polypeptides is noted to be monodispersed, which is crucial for their effectiveness.
Career Highlights
Régis Boehringer is associated with Bright Peak Therapeutics AG, where he continues to advance his research and innovations. His work is pivotal in the ongoing quest for effective cancer treatments, showcasing his commitment to improving patient outcomes through scientific discovery.
Collaborations
Régis has collaborated with esteemed colleagues such as Vijaya Raghavan Pattabiraman and Roberto Iacone. These partnerships enhance the research and development efforts at Bright Peak Therapeutics AG, fostering a collaborative environment for innovation.
Conclusion
Régis Boehringer's contributions to the field of modified IL-2 polypeptides represent a significant advancement in cancer treatment. His innovative approach and dedication to research continue to inspire progress in biomedicine.